<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34865592</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8336</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert review of anti-infective therapy</Title><ISOAbbreviation>Expert Rev Anti Infect Ther</ISOAbbreviation></Journal><ArticleTitle>Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study.</ArticleTitle><Pagination><StartPage>781</StartPage><EndPage>787</EndPage><MedlinePgn>781-787</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14787210.2022.2015326</ELocationID><Abstract><AbstractText Label="BACKGROUND">Hydroxychloroquine had attracted significant attention in the initial phases of the COVID-19 pandemic but current recommendations do not support its use. However, the evidence against its use as pre-exposure prophylaxis have been of low to moderate quality and have been limited by high risk of bias.</AbstractText><AbstractText Label="METHODS">Following institutional ethics committee approval, healthcare workers (n&#xa0;=&#xa0;1294) completing their first week-long COVID in-patient duty, subsequent institutional quarantine and RT-PCR testing for COVID-19 infection were included for this prospective cohort study. Demographic data, hydroxychloroquine usage and related adverse effects were captured through a 'Caring for the Caregivers' surveillance system. A chi-Square test of independence was used to determine the effect of hydroxychloroquine prophylaxis.</AbstractText><AbstractText Label="RESULTS">Among the 1294 participants (age: 31&#xa0;&#xb1;&#xa0;7&#xa0;years, 61% women), 273 (21.1%) healthcare workers used hydroxychloroquine prophylaxis as per Indian Council of Medical Research recommendations and 83/1294 (6.4%) tested positive after their duty. There was no significant difference in COVID-19 incidence between those on hydroxychloroquine prophylaxis and those not on it (5.9% vs 6.6%, &#x3c7;<sup>2</sup>&#xa0;=&#xa0;0.177, p =&#xa0;0.675; RR&#xa0;=&#xa0;0.89, 95% CI - 0.53 to 1.52). There were no significant adverse effects to hydroxychloroquine usage.</AbstractText><AbstractText Label="CONCLUSION">This study demonstrated no benefit of hydroxychloroquine prophylaxis and provides quality evidence against its use in COVID-19 prevention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Akshay</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4111-5424</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, MS Ramaiah Medical College, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veluswamy</LastName><ForeName>Sundar Kumar</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0003-2241-6229</Identifier><AffiliationInfo><Affiliation>Department of Physiotherapy, MS Ramaiah Medical College.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthy Living for Pandemic Event Protection (Hl- Pivot) Network, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shankarappa</LastName><ForeName>Banashankari Gunjiganur</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Department of Microbiology, MS Ramaiah Medical College.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Rithika Manjunatha</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Medical student, MS Ramaiah Medical College Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umesh</LastName><ForeName>Nethravathi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Office of Nursing Superintendent, MS Ramaiah Medical College Hospital Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Lissy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Office of Nursing Superintendent, MS Ramaiah Medical College Hospital Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Lysamma</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Office of Nursing Superintendent, MS Ramaiah Memorial Hospital, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shetty</LastName><ForeName>Naresh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Caring for the Caregivers Surveillance System, MS Ramaiah Medical College Hospitals.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Anti Infect Ther</MedlineTA><NlmUniqueID>101181284</NlmUniqueID><ISSNLinking>1478-7210</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065129" MajorTopicYN="Y">Pre-Exposure Prophylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chemoprevention</Keyword><Keyword MajorTopicYN="N">drug-related side effects and adverse reactions</Keyword><Keyword MajorTopicYN="N">health personnel</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34865592</ArticleId><ArticleId IdType="pmc">PMC8726004</ArticleId><ArticleId IdType="doi">10.1080/14787210.2022.2015326</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bourgeault IL, Maier CB, Dieleman M, et al. The COVID-19 pandemic presents an opportunity to develop more sustainable health workforces. Hum Resour Health. 2020;18(1):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7602762</ArticleId><ArticleId IdType="pubmed">33129313</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LH, Drew DA, Graham MS, et al. Coronavirus pandemic epidemiology consortium. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020;5:e475&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491202</ArticleId><ArticleId IdType="pubmed">32745512</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook TM. Personal protective equipment during the coronavirus disease (COVID) 2019 pandemic &#x2013; a narrative review. Anaesthesia. 2020;75(7):920&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">32246849</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Kubota Y, Chernov M, et al. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. Med Hypotheses. 2020;144:109848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247509</ArticleId><ArticleId IdType="pubmed">32512490</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutolo M, Paolino S, Smith V. Evidences for a protective role of vitamin D in COVID-19. RMD Open. 2020;6(3):e001454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7771215</ArticleId><ArticleId IdType="pubmed">33372031</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade BS, Rangel FS, Santos NO, et al. Repurposing approved drugs for guiding COVID-19 prophylaxis: a systematic review. Front Pharmacol. 2020;11:590598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772842</ArticleId><ArticleId IdType="pubmed">33390967</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7078228</ArticleId><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>Niburski K, Niburski O. Impact of Trump&#x2019;s promotion of unproven COVID-19 treatments and subsequent internet trends: observational study. J Med Internet Res. 2020;22(11):e20044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7685699</ArticleId><ArticleId IdType="pubmed">33151895</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7274621</ArticleId><ArticleId IdType="pubmed">32511943</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh H, Chauhan P, Kakkar AK. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: the journey so far and the road ahead. Eur J Pharmacol. 2021;890:173717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606072</ArticleId><ArticleId IdType="pubmed">33152333</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian Council of Medical Research . Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection. [Internet] 2020. [updated 2020 May
22; cited 2021 May
22; cited 2021 May
22; cited 2021 May
22]. Available from: https://www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_the_use_of_HCQ_SARS_CoV2_infection.pdf</Citation></Reference><Reference><Citation>Bhattacharya R, Chowdhury S, Nandi A, et al. Pre-exposure hydroxychloroquine prophylaxis for covid-19 in healthcare workers: a retrospective cohort. Int J Res Med Sci. 2020;9(1):89&#x2013;96.</Citation></Reference><Reference><Citation>Barnabas RV, Brown ER, Bershteyn A, et al. Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection: a randomized trial. Ann Intern Med. 2021;174(3):344&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7732017</ArticleId><ArticleId IdType="pubmed">33284679</ArticleId></ArticleIdList></Reference><Reference><Citation>Grau-Pujol B, Camprub&#xed; D, Marti-Soler H, et al. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial. Res Square. 2020. DOI:10.21203/rs.3.rs-72132/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-72132/v1</ArticleId><ArticleId IdType="pmc">PMC8591593</ArticleId><ArticleId IdType="pubmed">34781981</ArticleId></ArticleIdList></Reference><Reference><Citation>Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med. 2021;181(2):195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7527945</ArticleId><ArticleId IdType="pubmed">33001138</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial. Clin Infect Dis. 2021;72(11):e835&#x2013;e843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665393</ArticleId><ArticleId IdType="pubmed">33068425</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289276</ArticleId><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitj&#xe0; O, Marc CM, Ubals M, et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Engl J Med. 2021;384:417&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7722693</ArticleId><ArticleId IdType="pubmed">33289973</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation . WHO Coronavirus (COVID-19) dashboard. [Internet] 2021. cited 2021 Oct
16]. Available from: https://covid19.who.int/</Citation></Reference><Reference><Citation>Burki T. Global COVID-19 vaccine inequity. Lancet Infect Dis. 2021;21(7):922&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221728</ArticleId><ArticleId IdType="pubmed">34174236</ArticleId></ArticleIdList></Reference><Reference><Citation>Stricker RB, Fesler MC. Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers from india: a meta-analysis. J Infect Public Health. 2021;14(9):1161&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340552</ArticleId><ArticleId IdType="pubmed">34391171</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation . Coronavirus disease (COVID-19): solidarity Trial and hydroxychloroquine. [updated
2020 Jun
19; cited 2021 Oct
16]. Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-hydroxychloroquine.</Citation></Reference><Reference><Citation>Martins-Filho PR, Ferreira LC, Heimfarth L, et al. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Lancet Reg Health Am. 2021; 2: 100062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8403035</ArticleId><ArticleId IdType="pubmed">34485970</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinesh B, Cs J, Kaur CP, et al. Hydroxychloroquine for SARS CoV2 prophylaxis in healthcare workers - a multicentric cohort study assessing effectiveness and safety. J Assoc Physicians India. 2021;69(6):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">34472778</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Drugs to prevent COVID-19: a WHO living guideline. [updated
2021 Mar
19; cited 2021 Oct
16]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-prophylaxes-2021-1</Citation><ArticleIdList><ArticleId IdType="pubmed">35917395</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruciani M, Pati I, Masiello F, et al. Ivermectin for prophylaxis and treatment of COVID-19: a systematic review and meta-analysis. Diagnostics (Basel). 2021. Sep 8;11(9):1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8470309</ArticleId><ArticleId IdType="pubmed">34573986</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon S. Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature. 2021. Aug;596(7871):173&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">34341573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>